DDX3X induces primary EGFR-TKI resistance based on intratumor heterogeneity in lung cancer cells harboring EGFR-activating mutations.

by Koichiro Nozaki, Hiroshi Kagamu, Satoshi Shoji, Natsue Igarashi, Aya Ohtsubo, Masaaki Okajima, Satoru Miura, Satoshi Watanabe, Hirohisa Yoshizawa, Ichiei Narita
Published 2014-01-01

Prognostic significance of the radiologic features of pneumonitis induced by anti‐PD‐1 therapy

by Satoshi Watanabe, Takeshi Ota, Masachika Hayashi, Hiroyuki Ishikawa, Aya Otsubo, Satoshi Shoji, Koichiro Nozaki, Kosuke Ichikawa, Rie Kondo, Takao Miyabayashi, Satoru Miura, Hiroshi Tanaka, Tetsuya Abe, Masaaki Okajima, Masaki Terada, Takashi Ishida, Akira Iwashima, Kazuhiro Sato, Hirohisa Yoshizawa, Toshiaki Kikuchi
Published 2020-05-01

Efficacy of EGFR‐TKIs with or without upfront brain radiotherapy for EGFR‐mutant NSCLC patients with central nervous system metastases

by Yu Saida, Satoshi Watanabe, Tetsuya Abe, Satoshi Shoji, Koichiro Nozaki, Kosuke Ichikawa, Rie Kondo, Kenichi Koyama, Satoru Miura, Hiroshi Tanaka, Masaaki Okajima, Masaki Terada, Takashi Ishida, Hiroki Tsukada, Masato Makino, Akira Iwashima, Kazuhiro Sato, Naoya Matsumoto, Hirohisa Yoshizawa, Toshiaki Kikuchi
Published 2019-11-01

The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody via Continuation or Rechallenge After the Occurrence of Immune-Related Adverse Events

by Toshiya Fujisaki, Satoshi Watanabe, Takeshi Ota, Kohei Kushiro, Yusuke Sato, Miho Takahashi, Aya Ohtsubo, Satoshi Shoji, Koichiro Nozaki, Kosuke Ichikawa, Satoshi Hokari, Rie Kondo, Takao Miyabayashi, Tetsuya Abe, Satoru Miura, Hiroshi Tanaka, Masaaki Okajima, Masaki Terada, Naoya Matsumoto, Takashi Ishida, Akira Iwashima, Kazuhiro Sato, Hirohisa Yoshizawa, Nobumasa Aoki, Masachika Hayashi, Yasuyoshi Ohshima, Toshiyuki Koya, Toshiaki Kikuchi
Published 2021-09-01